Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Vaccines and Vaccine Adjuvants/Immunomodulators for Infectious Diseases 2.0
share announcement

Vaccines and Vaccine Adjuvants/Immunomodulators for Infectious Diseases 2.0

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 5686

Special Issue Editors

Prof. Dr. Jagadeesh Bayry

E-Mail Website
Guest Editor
Centre de Recherche des Cordeliers, Sorbonne Université, F-75006 Paris, France
Interests: immunology; immune homeostasis; immunotherapy; host-pathogen interaction
Special Issues, Collections and Topics in MDPI journals
Dr. Srinivasa Reddy Bonam

E-Mail Website
Guest Editor
Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX 77550, USA
Interests: DNA vaccine; immune responses; infectious disease; plasmids; vaccine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The importance of vaccination has gained much attention, again, due to the advent of COVID-19 pandemic. The pioneering vaccinology research of many scientists to eradicate and control various infectious diseases, including polio, Rinderpest and smallpox, diphtheria, rubella, measles, mumps, respectively, has come true via vaccines. However, despite decades of research, many diseases, including bacterial, fungal, parasitic and viral, are not having efficacious vaccines. The ultimate goal of vaccination is to generate a safe and effective long-term immune response against targeted disease.

Vaccine adjuvants and/or immunomodulators, either directly or indirectly, have become an indispensable component for many (if not all) vaccines, including RNA, DNA, recombinant proteins, inactivated and attenuated, and viral vector vaccines. Though limited number of adjuvants have entered clinical phase, various adjuvants/immunomodulators have been explored in the experimental vaccines against various diseases.  Although many adjuvants' precise mechanisms of action are not known, they enhance the immune response of antigen through modulation of innate and adaptive immune responses, thus providing long-lasting immunological memory.

We invite potential researchers to submit a research article or a comprehensive/mini/ opinion review article related to vaccines and vaccine adjuvants/immunomodulators against infectious diseases. The specific themes are, including but not limited to:

  • Development of novel vaccines against infectious diseases
  • Strategies to overcome the current challenges in the development of various vaccines against infectious diseases
  • Preparation of antigens for recombinant vaccines.
  • Role of adjuvants/immunomodulators in vaccines against infectious diseases
  • The potential use of novel delivery systems, including emulsions, liposomes, and other nano/microparticle-based systems, for vaccines
  • Effect of route of administration on vaccine efficacy
  • Characterisation and immunological evaluation of vaccine delivery systems
  • Immunopharmacological evaluation of vaccines and/or vaccine adjuvants/immunomodulators
  • Proof-of-concept studies of mechanisms of action of adjuvants/immunomodulator

Preference will be given to articles, which focus on emerging infectious agents (e.g., Coronavirus, Influenza, Hepatitis, Dengue, Malaria and others) in humans or animals. 

Prof. Dr. Jagadeesh Bayry
Dr. Srinivasa Reddy Bonam
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Related Special Issue

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Editorial

Jump to: Research

5 pages, 208 KiB  
Editorial
THEME: “Vaccines and Vaccine Adjuvants/Immunomodulators for Infectious Diseases”
by Sruthi Vijaya Retnakumar, Srinivasa Reddy Bonam, Haitao Hu and Jagadeesh Bayry
Vaccines 2023, 11(2), 383; https://doi.org/10.3390/vaccines11020383 - 7 Feb 2023
Cited by 2 | Viewed by 1763
Abstract
The discovery of vaccines has enabled the successful prevention of many deadly infectious diseases, decreased the overall mortality rate, and improved life expectancy worldwide [...] Full article
(This article belongs to the Special Issue Vaccines and Vaccine Adjuvants/Immunomodulators for Infectious Diseases 2.0)

Research

Jump to: Editorial

15 pages, 2341 KiB  
Article
Ag85a-S2 Activates cGAS-STING Signaling Pathway in Intestinal Mucosal Cells
by Sheng Dang, Wanyang Li, Shubo Wen, Yang Song, Meirong Bai, Shuyan Li, Zeliang Chen and Jingbo Zhai
Vaccines 2022, 10(12), 2170; https://doi.org/10.3390/vaccines10122170 - 16 Dec 2022
Cited by 1 | Viewed by 1380
Abstract
Brucellosis is a zoonotic disease caused by Gram-negative bacteria. Most of the brucellosis vaccines in the application are whole-bacteria vaccines. Live-attenuated vaccines are widely used for brucellosis prevention in sheep, goats, pigs, and cattle. Thus, there is also a need for an adjuvanted [...] Read more.
Brucellosis is a zoonotic disease caused by Gram-negative bacteria. Most of the brucellosis vaccines in the application are whole-bacteria vaccines. Live-attenuated vaccines are widely used for brucellosis prevention in sheep, goats, pigs, and cattle. Thus, there is also a need for an adjuvanted vaccine for human brucellosis, because the attenuated Brucella vaccines now utilized in animals cause human illness. Here, we developed a live-attenuated Brucella suis strain 2 vaccine (S2) adjuvanted with Ag85a (Ag85a-S2). We found that Ag85a-S2 activated cGAS-STING pathways both in intestinal mucosal cells in vivo and in the BMDM and U937 cell line in vitro. We demonstrated that the cGAS knockout significantly downregulated the abundance of interferon and other cytokines induced by Ag85a-S2. Moreover, Ag85a-S2 triggered a stronger cellular immune response compared to S2 alone. In sum, Ag85a-S2-mediated enhancement of immune responses was at least partially dependent on the cGAS-STING pathway. Our results provide a new candidate for preventing Brucella pathogens from livestock, which might reduce the dosage and potential toxicity compared to S2. Full article
(This article belongs to the Special Issue Vaccines and Vaccine Adjuvants/Immunomodulators for Infectious Diseases 2.0)
►▼ Show Figures

Figure 1

11 pages, 3104 KiB  
Article
Flagellin Improves the Immune Response of an Infectious Bursal Disease Virus (IBDV) Subunit Vaccine
by Asad Murtaza, Haroon Afzal, Thu-Dung Doan, Guan-Ming Ke and Li-Ting Cheng
Vaccines 2022, 10(11), 1780; https://doi.org/10.3390/vaccines10111780 - 22 Oct 2022
Cited by 3 | Viewed by 1964
Abstract
Flagellin activates the immune system through Toll-like receptor 5 (TLR5) and can work as an adjuvant for subunit vaccines. In this study, we tested the adjuvancy of two different N-terminal fragments of flagellin, (1) FliC99, residues 1–99, and (2) FliC176 [...] Read more.
Flagellin activates the immune system through Toll-like receptor 5 (TLR5) and can work as an adjuvant for subunit vaccines. In this study, we tested the adjuvancy of two different N-terminal fragments of flagellin, (1) FliC99, residues 1–99, and (2) FliC176, residues 1–176, to incorporate larger areas of the hotspot region for potentially higher levels of TLR5 activation and immune response. A truncated version of the VP2 protein (name tVP2, residues 199–356) of the Infectious bursal disease virus (IBDV) was genetically linked to the flagellin constructs, and the immune response was evaluated in chickens. Results showed that both chimeric antigen–adjuvant constructs increased humoral (total IgG titers), cellular and cytokine immune response (IL-4, IFN-γ). The resulting antibody also successfully neutralized IBDV. We conclude that the N-terminus of flagellin can act as an immune activator to enhance vaccine efficacy. Full article
(This article belongs to the Special Issue Vaccines and Vaccine Adjuvants/Immunomodulators for Infectious Diseases 2.0)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop